JP2016528255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016528255A5 JP2016528255A5 JP2016534827A JP2016534827A JP2016528255A5 JP 2016528255 A5 JP2016528255 A5 JP 2016528255A5 JP 2016534827 A JP2016534827 A JP 2016534827A JP 2016534827 A JP2016534827 A JP 2016534827A JP 2016528255 A5 JP2016528255 A5 JP 2016528255A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- pyridin
- hydroxy
- amino
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 11
- 206010012289 Dementia Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- GRZMKKUGHIECFK-MNOVXSKESA-N (2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one Chemical compound C1([C@H](O)[C@@H](N)C(=O)N2CCCC2)=CC=NC=C1 GRZMKKUGHIECFK-MNOVXSKESA-N 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 201000007201 aphasia Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000020358 Learning disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 206010039966 Senile dementia Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 201000003723 learning disability Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000006888 Agnosia Diseases 0.000 claims 1
- 241001047040 Agnosia Species 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003062 Apraxia Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010010254 Concussion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 1
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 208000024571 Pick disease Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 208000018642 Semantic dementia Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000037132 Subdural Chronic Hematoma Diseases 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 230000009514 concussion Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000018459 dissociative disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 claims 1
- 230000004907 flux Effects 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 claims 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 150000003892 tartrate salts Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361866155P | 2013-08-15 | 2013-08-15 | |
| US61/866,155 | 2013-08-15 | ||
| PCT/US2014/051007 WO2015023816A1 (en) | 2013-08-15 | 2014-08-14 | (-)-(2r,3s)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (l)-(+) tartrate salt, its method of production and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016528255A JP2016528255A (ja) | 2016-09-15 |
| JP2016528255A5 true JP2016528255A5 (enExample) | 2017-09-21 |
| JP6486358B2 JP6486358B2 (ja) | 2019-03-20 |
Family
ID=51398940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534827A Active JP6486358B2 (ja) | 2013-08-15 | 2014-08-14 | （−）−（２ｒ，３ｓ）−２−アミノ−３−ヒドロキシ−３−ピリジン−４−イル−１−ピロリジン−１−イル−プロパン−１−オン・（ｌ）−（＋）酒石酸塩、その製造方法及び使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9242935B2 (enExample) |
| EP (2) | EP3336079A1 (enExample) |
| JP (1) | JP6486358B2 (enExample) |
| CN (2) | CN108794386B (enExample) |
| CA (1) | CA2921385C (enExample) |
| DK (1) | DK3033327T3 (enExample) |
| ES (1) | ES2664749T3 (enExample) |
| HU (1) | HUE036381T2 (enExample) |
| NO (1) | NO2960430T3 (enExample) |
| PL (1) | PL3033327T3 (enExample) |
| PT (1) | PT3033327T (enExample) |
| SI (1) | SI3033327T1 (enExample) |
| WO (1) | WO2015023816A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3033327T3 (en) | 2013-08-15 | 2018-04-16 | Allergan Inc | (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L) - (+) - tartrate salt, PROCEDURE FOR MANUFACTURING AND USING THEREOF |
| US9992703B2 (en) * | 2016-04-04 | 2018-06-05 | Cisco Technology, Inc. | Insertion of management packet into a deterministic track |
| JP2025506178A (ja) * | 2022-02-11 | 2025-03-07 | ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド | 精神状態及び障害を処置するための（ａｍｐａｒ－ｐａｍ）－ｎｍｄａ受容体拮抗薬組合せ療法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5545745A (en) * | 1994-05-23 | 1996-08-13 | Sepracor, Inc. | Enantioselective preparation of optically pure albuterol |
| US6835831B2 (en) * | 2001-11-26 | 2004-12-28 | Genzyme Corporation | Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors |
| US20090088433A1 (en) * | 2005-01-26 | 2009-04-02 | Bertrand Leblond | Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008011478A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
| WO2008011483A2 (en) * | 2006-07-19 | 2008-01-24 | Allergan, Inc. | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds |
| DK2481407T3 (en) * | 2007-03-06 | 2019-01-07 | Allergan Inc | RELATIONSHIPS TO USE IN TREATMENT OF COGNITIVE DISORDERS |
| US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
| US20100105687A1 (en) * | 2007-03-06 | 2010-04-29 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
| DK3033327T3 (en) | 2013-08-15 | 2018-04-16 | Allergan Inc | (-) - (2R, 3S) -2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L) - (+) - tartrate salt, PROCEDURE FOR MANUFACTURING AND USING THEREOF |
-
2014
- 2014-08-14 DK DK14755535.3T patent/DK3033327T3/en active
- 2014-08-14 US US14/459,551 patent/US9242935B2/en active Active
- 2014-08-14 WO PCT/US2014/051007 patent/WO2015023816A1/en not_active Ceased
- 2014-08-14 SI SI201430670T patent/SI3033327T1/en unknown
- 2014-08-14 JP JP2016534827A patent/JP6486358B2/ja active Active
- 2014-08-14 CN CN201810276093.9A patent/CN108794386B/zh active Active
- 2014-08-14 CA CA2921385A patent/CA2921385C/en active Active
- 2014-08-14 EP EP18150038.0A patent/EP3336079A1/en not_active Withdrawn
- 2014-08-14 CN CN201480050583.7A patent/CN105555765B/zh active Active
- 2014-08-14 EP EP14755535.3A patent/EP3033327B1/en active Active
- 2014-08-14 PT PT147555353T patent/PT3033327T/pt unknown
- 2014-08-14 ES ES14755535.3T patent/ES2664749T3/es active Active
- 2014-08-14 HU HUE14755535A patent/HUE036381T2/hu unknown
- 2014-08-14 PL PL14755535T patent/PL3033327T3/pl unknown
-
2015
- 2015-06-26 NO NO15174003A patent/NO2960430T3/no unknown
- 2015-12-21 US US14/976,926 patent/US9540328B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512951A5 (enExample) | ||
| RS52743B (sr) | (2s,3r)-n-(2-((3-piridinil)metil)-1-azabiciklo[2.2.2]okt-3-il)benzofuran-2-karboksamid, novi oblici soli i postupci za njihovu upotrebu | |
| JP2020502092A5 (enExample) | ||
| RU2014145682A (ru) | Органические соединения | |
| MX2017013483A (es) | Compuestos y su uso como inhibidores de ?-secretasa 1 (bace1). | |
| HRP20141178T1 (hr) | Äśvrsti gama karbolin kondenziran sa supstituiranim heterociklusom | |
| CL2010000129A1 (es) | Compuestos derivados de benzazepinas fusionadas sustituidas, moduladores del receptor de acetilcolina; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de trastornos del snc tales como esquizofrenia, demencia, enfermedad del alzheimer, esclerosis multiple, entre otras. | |
| JP2005524675A (ja) | α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド | |
| CN103588659A (zh) | 手性酰胺和胺的制备 | |
| JP5921576B2 (ja) | ピリドン誘導体を含む医薬組成物 | |
| JP2016528255A5 (enExample) | ||
| SMT201700142T1 (it) | SALE DI CAMSILATO DI (1r, 1’R, 4R)-4-METOSSI-5’’-METIL-6’-[5-(PROP-1-IN-1-IL)PIRIDIN-3-IL]-3’H-DISPIRO[CICLOESANO-1,2’-INDEN-1’2’-IMIDAZOLO]-4’’-AMMINA E SUE FORME CRISTALLINE PER IL TRATTAMENTO DI PATOLOGIE A[BETA]-CORRELATE COME PER ESEMPIO LA MALATTIA DI ALZHEIMER | |
| JP2014205695A (ja) | アザアダマンタンエステルおよびカーバメート誘導体ならびにそれらの使用方法 | |
| JP2019534327A5 (enExample) | ||
| WO2016029218A4 (en) | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | |
| US8198296B2 (en) | Sub-type selective azabicycloalkane derivatives | |
| US20210198218A1 (en) | Compounds for therapeutic use | |
| JP2011516588A5 (enExample) | ||
| ECSP10010397A (es) | Preparacion y separacion enantiomerica de 7-(3- piridinilo)-1,7-diazaspiro[4.4] nonano y formas novedosas de sal de la mezcla racemica y enantiomeros | |
| AR079103A1 (es) | Compuesto de sal de mesilato de (s) -2-(4-(3-fluoro-benciloxi)-bencilamino)-propionamida, forma polimorfica (nf6) , composicion farmaceutica, uso del mismo para la preparacion de un medicamento y su procesos de preparacion | |
| JP2010522203A (ja) | ４−置換アザアダマンタン誘導体およびそれの使用方法 | |
| SI3033327T1 (en) | (-) - (2R, 3S) -2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYROLIDIN-1-ILL- PROPAN- 1-ON (L) - (+) TARTRATED SOLE AND METHOD FOR ITS PRODUCTION AND ITS USE | |
| NZ575573A (en) | Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof | |
| JP2020520936A5 (enExample) | ||
| FI3625213T3 (fi) | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt |